pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

AHRQ cuts $109 million in health services research grants, ending 78 projects early

Jul 22, 2026·read at STAT ↗RegulatoryNegative

AHRQ announced that dozens of health services research grants will stop early, affecting about $109 million still to be spent.

The agency said it is reshaping its discretionary award portfolio to better prioritize its work, and sent "non-award" letters to investigators.

AcademyHealth reported at least 78 grants, originally totalling $200 million, are impacted, leaving researchers uncertain about the future of the field.

Researchers had been waiting for renewal decisions and now face funding gaps, raising concerns about the continuity of health services research.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Federal health quality research grants worth $109 million ended early”

read at STAT ↗
540 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
Rare Disease

related stories

  • May 12STAT+: Hims’ sales miss as telehealth competition growsSTAT
  • May 12STAT+: Capsida says it still doesn’t know what caused gene therapy deathSTAT
  • May 12A year after Vertex’s big launch, pain drug research faces a pivotal momentBioPharma Dive
  • May 11No FDA permission, no problem: New flavored vape policy worries expertsSTAT
  • May 11STAT+: Astellas treatment offers new hope to a devastated rare disease communitySTAT